Severe iron overload in Blackfan-Diamond anemia: A case-control study

American Journal of Hematology

Volumn 84, Issue 11, 2009, Pages 729-732

  Roggero, Simona ^a   Quarello, Paola ^b   Vinciguerra, Tiziana ^a   Longo, Filomena ^a   Piga, Antonio ^a   Ramenghi, Ugo ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DEFEROXAMINE MESYLATE; IRON;

ADOLESCENT; ADULT; ARTICLE; BLACKFAN DIAMOND ANEMIA; BLOOD TRANSFUSION; BLOOD TRANSFUSION REACTION; CASE CONTROL STUDY; CHELATION THERAPY; CHILD; CLINICAL ARTICLE; CLINICAL EVALUATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE SEVERITY; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; IRON BLOOD LEVEL; IRON CHELATION; IRON INTAKE; IRON OVERLOAD; LIVER LEVEL; MALE; MEDICAL RECORD REVIEW; PRESCHOOL CHILD; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; THALASSEMIA MAJOR;

ADOLESCENT; ADULT; ANEMIA, DIAMOND-BLACKFAN; BETA-THALASSEMIA; BLOOD TRANSFUSION; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; IRON OVERLOAD; ITALY; LIVER; MAGNETIC RESONANCE IMAGING; MALE; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 70449567430     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21541     Document Type: Article

References (24)

1. Piga A. Survival improvement in thalassemia: Who should take the credit?. Haematologica 2006;91:1154B.
2. Ambruso DR, Mahony BS, Githens JH, Rhoades ED. Effect of subcutaneous deferoxamine and oral vitamin C on iron excretion in congenital hypoplastic anemia and refractory anemia associated with the 5q-syndrome. Am J Pediatr Hematol Oncol 1982;4:115-123.
3. Beck W, Stubbe P, Tillmann W. Endocrine studies in Blackfan-Diamond anemia: Evidence for hypothalamic-pituitary dysfunction under frequent transfusion therapy. Eur J Pediatr 1980;135:103-105. (Pubitemid 11216978)
4. Campagnoli MF, Garelli E, Quarello P, et al. Molecular basis of Diamond-Blackfan anemia: New findings from the Italian registry and a review of the literature. Haematologica 2004;89:480-489. (Pubitemid 38798553)
5. Vlachos A, Ball S, Dahl N, et al. Diagnosing and treating Diamond Blackfan anaemia: Results of an international clinical consensus conference. Br J Haematol 2008;142:859-876.
6. Lipton JM, Atsidaftos E, Zyskind I, Vlachos A. Improving clinical care and elucidating the pathophysiology of Diamond Blackfan anemia: An update from the Diamond Blackfan Anemia Registry. Pediatr Blood Cancer 2006;46: 558-564.
7. Cappellini M-D, Cohen A, Eleftheriou A, et al. Guidelines for the clinical management of thalassemia, 2nd editon revised, 2008.
8. Angelucci EBG, Mclaren CE, Ripalti M, et al. Hepatic iron concentration and total body iron stores in thalassemia. N Engl J Med 2000;343:327-331. (Pubitemid 30616698)
9. Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006;107:3455-3462.
10. Roper-Bouchet M, Turlin B, Graham G. Drying methods affect the wet:Dry weight ratio of liver tissue samples and impact liver iron content measurements. BioIron 2005;107:274 (Abstract).
11. Olivieri NF, Nathan DG, Macmillan JH, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 1994;331:574-578. (Pubitemid 24265699)
12. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997;89:739-761.
13. Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2* magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001;22:2140-2141 (Pubitemid 33139463)
14. Pennell DJ. T2* magnetic resonance and myocardial iron in thalassemia. Ann N Y Acad Sci 2005;1054:373-378. (Pubitemid 43031044)
15. Pakbaz Z, Fischer R, Fung E, et al. Serum ferritin underestimates liver iron concentration in transfusion independent thalassemia patients as compared to regularly transfused thalassemia and sickle cell patients. Pediatr Blood Cancer 2007;49:329-332. (Pubitemid 47236225)
16. Henter JI, Karlen J. Fatal agranulocytosis after deferiprone therapy in a child with Diamond-Blackfan anemia. Blood 2007;109:5157-5159. (Pubitemid 46890530)
17. Tchernia G, Vichinsky E, Jeng M, et al. Presented at the once-daily oral iron chelator ICL670 is well tolerated and effective in treating transfusional iron overload in Diamond-Blackfan anemia patients 10th EHA Meeting, Stockholm, 2005.
18. Porter J, Galanello R, Saglio G, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): A 1-yr prospective study. Eur J Haematol 2008;80: 168-176.
19. Vichinsky E. Clinical application of deferasirox: Practical patient management. Am J Hematol 2008;83:398-402. (Pubitemid 351614754)
20. Porter JB. Concepts and goals in the management of transfusional iron overload. Am J Hematol 2007;82:1136-1139. (Pubitemid 350221244)
21. Wood JC. Magnetic resonance imaging assessment of excess iron in thalassemia, sickle cell disease and other iron overload diseases. Hemoglobin 2008;32:85-96. (Pubitemid 351264532)
22. Origa RBS, Argiolas GM, Bina P, et al. No evidence of cardiac iron in 20 never-or minimally-transfused patients with thalassemia intermedia. Haematologia 2008;93:1095-1096. (Pubitemid 351957030)
23. Nemeth E. Iron regulation and erythropoiesis. Curr Opin Hematol 2008;15:169-175.
24. Hershko C. Iron loading and its clinical implications. Am J Hematol 2007;82:1147-1148. (Pubitemid 350221247)